Ga-68 PET/CT scan for people with cancer
Part of Cancer clinical trials.
This trial looks at using a specific PET/CT scan (a whole-body imaging test) to help evaluate cancer that is confirmed or suspected. If you are eligible, you may receive this scan soon after a recent FDG PET/CT to compare or improve how cancers are identified.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed or suspected cancer
- You had an FDG PET/CT scan within the last week
- You can sign written informed consent
- You are not pregnant
- You are not breastfeeding, if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a specific PET/CT scan using a radioactive tracer can detect or evaluate cancers. It may help doctors see where cancer is in the body more clearly.
This trial looks at a specific PET/CT scan using a tracer called 68Ga to create detailed images of prostate cancer. It may help doctors see where cancer is in the body more clearly.
This trial tests a new radioactive tracer called 68Ga-SFB6-ZN01 for PET/CT scans in people with suspected or confirmed solid tumors. It aims to see if this tracer can help find cancer or detect recurrence after treatment.
This trial tests a PET scan (a type of imaging) that targets cells in the body that help support cancers. It may help doctors better see where cancer-associated cells are located, which could guide future cancer care.
This early-phase study tests a special whole-body scan (PET/CT) that uses injected tracers to help show where lung cancer may be. It may help researchers see tumors more clearly and compare different tracers during the same time window.
This early-phase study tests special PET/CT scans using a radioactive tracer to see cancer areas that have specific targets. It may help doctors better visualize tumors and plan next steps, using scans that you may already be familiar with (FDG) plus targeted tracers.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.